[go: up one dir, main page]

ATE342356T1 - Prostata-spezifisches membranantigen - Google Patents

Prostata-spezifisches membranantigen

Info

Publication number
ATE342356T1
ATE342356T1 AT94900538T AT94900538T ATE342356T1 AT E342356 T1 ATE342356 T1 AT E342356T1 AT 94900538 T AT94900538 T AT 94900538T AT 94900538 T AT94900538 T AT 94900538T AT E342356 T1 ATE342356 T1 AT E342356T1
Authority
AT
Austria
Prior art keywords
provides
antigen
prostate
nucleic acid
specific membrane
Prior art date
Application number
AT94900538T
Other languages
English (en)
Inventor
Ron S Israeli
Warren D W Heston
William R Fair
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25520775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE342356(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE342356T1 publication Critical patent/ATE342356T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94900538T 1992-11-05 1993-11-05 Prostata-spezifisches membranantigen ATE342356T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97333792A 1992-11-05 1992-11-05

Publications (1)

Publication Number Publication Date
ATE342356T1 true ATE342356T1 (de) 2006-11-15

Family

ID=25520775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94900538T ATE342356T1 (de) 1992-11-05 1993-11-05 Prostata-spezifisches membranantigen

Country Status (10)

Country Link
US (1) US5538866A (de)
EP (3) EP1757694A3 (de)
JP (2) JP4204642B2 (de)
AT (1) ATE342356T1 (de)
CA (1) CA2147499C (de)
DE (1) DE69334071T2 (de)
DK (1) DK0668777T3 (de)
ES (1) ES2276390T3 (de)
PT (1) PT668777E (de)
WO (1) WO1994009820A1 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) * 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
ATE342356T1 (de) * 1992-11-05 2006-11-15 Sloan Kettering Inst Cancer Prostata-spezifisches membranantigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7070782B1 (en) * 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
US20030109469A1 (en) * 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
WO1996026272A1 (en) * 1995-02-24 1996-08-29 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
EP0725139A3 (de) * 1995-02-03 1997-11-26 Bayer Corporation Rekombinantes prostat-spezifisches Antigen und seiner Verwendung als Immunoassay-Kalibrator
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US6379669B1 (en) * 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US20040253246A1 (en) * 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
BR9708082A (pt) * 1996-03-15 1999-07-27 Corixa Corp Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DK0914155T3 (da) * 1996-03-25 2006-06-26 Medarex Inc Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
EP0891550A1 (de) * 1996-04-05 1999-01-20 The Johns Hopkins University School Of Medicine Verfahren zur anreicherung von seltenen zellen
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US5817481A (en) * 1996-05-21 1998-10-06 Smithkline Beecham Corporation Polynucleotides and polypeptides associated with benign prostatic hypertrophy
US5795877A (en) * 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US5902817A (en) * 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
NZ333235A (en) 1996-06-17 2000-06-23 Guilford Pharm Inc Methods of cancer treatment using naaladase inhibitors
US6025345A (en) * 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5863536A (en) * 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
EP1243653A3 (de) * 1996-09-06 2003-01-02 The Regents Of The University Of California E25a Protein, Methoden zur Herstellung und Verwendung
US6093800A (en) * 1996-09-06 2000-07-25 The Regents Of The University Of California E25a protein, methods for production and use thereof
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
NZ334780A (en) 1996-09-27 2000-12-22 Guilford Pharm Inc Use of a NAALADase inhibitor for treating glutamate abnormality and effecting neuronal activity in animals
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7008772B1 (en) 1997-02-25 2006-03-07 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP0972201B1 (de) * 1997-02-25 2005-08-17 Corixa Corporation Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
US7270980B2 (en) 1997-02-25 2007-09-18 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6657056B2 (en) 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
BR9808881A (pt) 1997-02-25 2001-09-11 Corixa Corp Compostos para imunoterapia de câncer de próstata e métodos para seu uso
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP2060630B1 (de) * 1997-04-10 2012-10-24 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, PCA3-Gene und Verfahren zu ihrer Verwendung
US6194152B1 (en) * 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
EP1489100B1 (de) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimäre Fusionsproteine zur Verwendung für gezielte Immuntherapie und allgemeine Immunerregung
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
WO1999037778A2 (en) * 1998-01-26 1999-07-29 Genquest, Inc. Compositions and methods for detecting and treating prostate cancer
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CA2328076C (en) * 1998-04-15 2009-10-06 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
EP1571141A2 (de) 1998-07-06 2005-09-07 Guilford Pharmaceuticals Inc. Naaladase-Hemmer, anwendbar als pharmazeutische Verbindungen und Zusammensetzungen
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
GB9828840D0 (en) * 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
CA2360073C (en) * 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
IL145142A0 (en) * 1999-03-01 2002-06-30 Commw Scient Ind Res Org Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
CA2368655A1 (en) 1999-04-08 2000-10-19 Gregory M. Glenn Dry formulation for transcutaneous immunization
EP1177207A4 (de) * 1999-04-09 2003-06-04 Sloan Kettering Inst Cancer Für das prostataspezifische membran-antigenartige gen kodierende dna und ihre verwendung
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
EP1221053A4 (de) * 1999-09-13 2004-12-22 Neil H Bander Verfahren zur isolierung von prostatischen epithelzellen aus sperma
ATE321857T1 (de) 1999-09-29 2006-04-15 Diagnocure Inc Pca3 mrna in gutartigen und bösartigen prostatageweben
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
ES2269366T3 (es) * 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
BR0112111A (pt) * 2000-06-29 2003-05-06 Merck Patent Gmbh Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
US6379550B1 (en) * 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
EP1328642A2 (de) * 2000-09-28 2003-07-23 Akzo Nobel N.V. Gen 4
EP1332227A4 (de) * 2000-10-16 2005-08-24 Gilead Sciences Inc Nukleinsäureliganden an dem prostata-spezifischen membranantigen
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2428011A1 (en) * 2000-11-20 2002-06-13 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
US6875886B2 (en) 2001-02-07 2005-04-05 Beth Israel Deaconess Medical Center, Inc. Modified PSMA ligands and uses related thereto
ES2393733T3 (es) * 2001-03-07 2012-12-27 Merck Patent Gmbh Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
EP1752160A3 (de) 2001-04-06 2007-05-30 Mannkind Corporation Epitop-Sequenzen
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
WO2003025196A2 (en) * 2001-05-16 2003-03-27 Ceptyr, Inc. Dsp-18 dual-specificity phosphatase
WO2002096460A1 (en) * 2001-05-30 2002-12-05 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP3184539A3 (de) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antikörper
US20040018519A1 (en) * 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
EP1454138B1 (de) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokine mit modulierter selektivität
SI2269656T1 (sl) 2002-07-15 2014-11-28 Board Of Regents, The University Of Texas System Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
EP1545610A4 (de) * 2002-09-06 2006-11-08 Mannkind Corp Epitop-sequenzen
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
EP1581794B1 (de) 2003-01-10 2008-09-17 Millennium Pharmaceuticals, Inc. Verfahren zur bestimmung des wiederauftretens von prostata krebs
EP2336189A1 (de) 2003-01-28 2011-06-22 Proscan RX Pharma Diagnose und Behandlung von Prostatakrebs
JP4824540B2 (ja) 2003-02-07 2011-11-30 ダイアノキュアー インク． サンプル中の前立腺癌を検出する方法
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
CA2529056C (en) 2003-06-17 2013-09-10 Mannkind Corporation Combinations of tumor-associated antigens in compositions for various types of cancers
US20050202020A1 (en) * 2004-01-09 2005-09-15 Jeffrey Ross Diagnosing and treating cancer
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US8354380B2 (en) * 2004-06-17 2013-01-15 Mannkind Corporation NY-ESO-1 peptide analogs
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
JP2008526760A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用
MX2007008013A (es) * 2004-12-29 2008-02-07 Mannkind Corp Metodos para producir, mejorar y sostener respuestas inmunes contra epitopos i-restringidos clase mhc por propositos profilacticos o terapeuticos.
EP1841467A4 (de) * 2005-01-14 2009-01-28 Cytogen Corp Kombinationskrebstherapie mit anti-psma-antikörpern
BRPI0607757A2 (pt) * 2005-02-18 2009-10-06 Medarex Inc anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo
MX2007009935A (es) 2005-02-18 2007-10-10 Medarex Inc Anticuerpos monoclonales que carecen de residuos fucosilo contra antigeno membranal especifico de prostata (psma).
WO2006093991A1 (en) * 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
US8084592B2 (en) 2005-06-17 2011-12-27 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
EP2385059A3 (de) 2005-06-17 2012-02-15 Mannkind Corporation Verfahren und Zusammensetzungen zum Auslösen von multivalenten Immunreaktionen gegen auf Krebszellen und Tumor-Stroma exprimierte dominante und subdominante Epitope
US7511119B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PRAME peptide analogues
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2007028167A2 (en) 2005-09-02 2007-03-08 Iomai Corporation Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof
ES2527961T3 (es) * 2005-09-26 2015-02-02 Medarex, L.L.C. Anticuerpos monoclonales humanos para CD70
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
IN2009KN02404A (de) * 2006-12-14 2015-08-07 Medarex Inc
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009127046A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
EP2326350B1 (de) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Verbindungen zur tötung von psma-expriemierenden und taxane-resistenten krebszellen
EP3378951B1 (de) 2008-09-20 2020-05-13 The Board of Trustees of the Leland Stanford Junior University Nicht invasive diagnose von aneuploidie durch sequenzierung
EP3495000A1 (de) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Verfahren und kits zur diagnose von krebs und vorhersage des therapeutischen werts
WO2010144800A1 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Methods and compositions for promoting a cell-mediated immune response
JP2013508415A (ja) 2009-10-23 2013-03-07 マンカインド コーポレイション 癌の免疫療法、および治療の方法
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
AU2011325893B2 (en) * 2010-11-12 2016-01-14 Inovio Pharmaceuticals, Inc Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
EP3211001B1 (de) 2010-12-22 2020-10-07 The Board of Trustees of the Leland Stanford Junior University Superagonisten und antagonisten von interleukin-2
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
EP3049445A4 (de) 2013-09-24 2017-10-25 Medicenna Therapeutics, Inc. Interleukin-2-fusionsproteine und verwendungen davon
EP3134102B1 (de) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonisten, partielle agonisten und antagonisten von interleukin-2
EP4137158A1 (de) 2015-08-07 2023-02-22 Imaginab, Inc. Gegen moleküle gerichtete antigenbindende konstrukte
WO2017177149A2 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
AU2019231205A1 (en) 2018-03-06 2020-09-24 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
CN112533943B (zh) 2018-06-01 2024-03-05 利兰斯坦福初级大学董事会 Il-13/il-4超级因子：免疫细胞靶向性构建体及其使用方法
EP4069731A4 (de) 2019-12-03 2024-05-29 Alamar Biosciences, Inc. Nukleinsäure-gekoppelter immun-sandwich-assay (nulisa)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
ATE342356T1 (de) * 1992-11-05 2006-11-15 Sloan Kettering Inst Cancer Prostata-spezifisches membranantigen

Also Published As

Publication number Publication date
EP0668777A1 (de) 1995-08-30
WO1994009820A1 (en) 1994-05-11
EP1757695A3 (de) 2008-02-27
CA2147499C (en) 2010-10-19
DE69334071D1 (de) 2006-11-23
US5538866A (en) 1996-07-23
EP1757694A2 (de) 2007-02-28
JPH08506005A (ja) 1996-07-02
EP1757694A3 (de) 2008-02-27
EP1757695A2 (de) 2007-02-28
EP0668777A4 (de) 1997-05-07
EP0668777B1 (de) 2006-10-11
DE69334071T2 (de) 2007-10-25
PT668777E (pt) 2007-01-31
DK0668777T3 (da) 2007-02-19
ES2276390T3 (es) 2007-06-16
CA2147499A1 (en) 1994-05-11
EP0668777B2 (de) 2011-02-09
JP2007014343A (ja) 2007-01-25
JP4204642B2 (ja) 2009-01-07
JP4202375B2 (ja) 2008-12-24

Similar Documents

Publication Publication Date Title
DK0668777T3 (da) Prostataspecifikt membran-antigen
DE69308162D1 (de) Methode zur amplification von ziel-gerichteten segmenten von nukleinsäure durch die ineinandergeschachtelte polymerase-kettenreaktion
DK13288A (da) T7 dna polymerase, fremgangsmaade og midler til fremstilling deraf samt fremgangsmaade til anvendelese deraf og kit indeholdende dna polymerase
SE8800864D0 (sv) Method of assaying of nucleic acids, a reagent combination and kit therefore
GB2274710B (en) Detection of nucleic acid sequences in a sample using an oligonucleotide immobilised on a waveguide
ATE159762T1 (de) Verfahren zur dns-sequenzbestimmung mit dns- polymerase von thermus aquaticus
DE69729122D1 (de) KüNSTLICHE FEHLHYBRIDISIERUNG
NO852022L (no) Nukleinsyre-hybridiseringsanalyse ved anvendelse av detekterbare anti-hybrid-antistoffer.
DE69428167D1 (de) Reagenz und Verfahren für reverse Transkription bei hoher Temperatur, verbunden mit einer Polymerase-Kettenreaktion
NO955119D0 (no) Salmonella identifisering ved polymerasekjedereaksjon
DE69531487D1 (de) Methode zur eliminierung von sequenzierartefakten
EP0128018A3 (en) Molecular genetic probe, and method of forming same, assay technique and kit using said molecular genetic probe
EP0382261A3 (de) DNS-Sonden gegen VNTR-Orte
SE9500341D0 (sv) Method for detecting DNA sequence variations
DE69019770D1 (de) Verfahren zur Reinigung, Vervielfachung und zum Nachweis einer Nukleinsäure.
ATE513061T1 (de) Diagnostisches verfahren und kit zur bestimmung des kell-blutgruppengenotyps
DE3567908D1 (en) Photoimmune detection of dna and rna
ATE118823T1 (de) Schnelles verfahren zur identifizierung einer spezifischen sequenz von nukleinsäure.
ATE250672T1 (de) Verfahren zum nachweis der aktivität von dns polymerasen
IT1207574B (it) Composizione profumata per il trattamento di articoli in pelle e cuoio.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0668777

Country of ref document: EP

RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties